Site Menu
Search Close Search
Search Close Search
Page Menu

John E. Harris, MD, PhD

Dr. Harris is the founding Director of the Vitiligo Clinic and Research Center, founding director of the Autoimmune Therapeutics Institute, and Professor and Chair in the Department of Dermatology at UMass Chan Medical School in Worcester, MA. Dr. Harris directs the Vitiligo Clinic and Research Center at UMass Chan Medical School, which incorporates a specialty clinic for the diagnosis and treatment of patients with vitiligo, as well as a vitiligo research laboratory. He uses basic, translational, and clinical research approaches to better understand autoimmunity in vitiligo, with a particular focus on developing more effective treatments.

He earned his MD and PhD degrees at UMass Chan Medical School, and his PhD thesis was focused on the loss of autoimmune tolerance in juvenile diabetes. He entered a combined research/residency program in dermatology at the University of Pennsylvania in Philadelphia, PA, and his postdoctoral research focused on the development of a mouse model of vitiligo with epidermal depigmentation. He now advises multiple graduate students, MD/PhD students, and postdoctoral fellows in his research laboratory at UMass Chan, and teaches medical students and residents in his vitiligo clinic. 

He has authored multiple research publications and textbook chapters on vitiligo and other topics and serves on a number of advisory boards and committees, including the Dermatology Foundation, Skin of Color Society, Vitiligo Working Group, Vitiligo Research Foundation, National Alopecia Areata Foundation, American Academy of Dermatology and the New England Dermatology Society, among others. He is an advisor and collaborator with multiple pharmaceutical companies, including AbbVie, Combe Inc, Genzyme/Sanofi, and Pfizer. 

Dr. Harris is an ad hoc reviewer on grant applications for the National Institutes of Health (NIH), Dermatology Foundation, and National Alopecia Areata Foundation, as well as multiple research journals, including Science Translational Medicine, the Journal of Clinical Investigation, the Journal of Investigative Dermatology, Pigment Cell & Melanoma Research, Experimental Dermatology, the Journal of the American Academy of Dermatology, JAMA Dermatology, and others. He receives generous grant support from the NIH, Dermatology Foundation, Kawaja Vitiligo Initiative, and the Vitiligo Research Foundation. He has lectured on vitiligo and other topics to local, regional, national, and international audiences.

Education

Postdoctoral Fellowship, University of Pennsylvania, Philadelphia, PA
Research: “Development of a Mouse Model to Study Vitiligo Pathogenesis”
Advisors: Dr. Laurence Turka, Dr. John Wherry, Dr. Christopher Hunter
Dermatology Residency, University of Pennsylvania, Philadelphia, PA
Medical Internship, UMass Chan Medical School, Worcester, MA
Ph.D., (Molecular Medicine), UMass Chan Medical School, Worcester, MA
Thesis Title: “The Molecular Mechanisms of T cell Clonal Anergy”
Advisors: Dr. Aldo Rossini, Dr. Michael Czech
M.D., UMass Chan Medical School, Worcester, MA
B.S., Premedicine, Gordon College, Wenham, MA

Membership in Vitiligo Societies:

Co-founder and Board Member, Vitiligo Working Group
Member Scientific Committee, Skin of Color Society
Board Member, Skin of Color Society
Basic Research Advisory Council, National Alopecia Areata Foundation
Scientific Advisory Board, Vitiligo Research Foundation
Board Member, New England Dermatology Society
Medical and Scientific Committee, Dermatology Foundation
Fellow, American Academy of Dermatology

Recent Lectures:

National/International Visiting Professor

  1. Speaker – Vitiligo, Molecular and Cellular Biology (MCB) Program, Dartmouth College
  2. Graduation Speaker, UMaryland Dept. Dermatology
  3. Grand Rounds Speaker – Vitiligo, Dept. of Dermatology, University of Minnesota
  4. Grand Rounds Speaker – Vitiligo, Dept. of Dermatology, Marshfield Clinic
  5. Grand Rounds Speaker – Vitiligo, Dept. of Dermatology, Indiana University
  6. Visiting Professor – Vitiligo, Dept. of Dermatology, University of California San Francisco
  7. Visiting Professor – Vitiligo, Dept. of Dermatology, Brown University
  8. Grand Rounds Speaker – Vitiligo, Dept. of Dermatology, University of Pennsylvania
  9. Grand Rounds Speaker – Vitiligo, Dept. of Dermatology, Henry Ford Hospital
  10. Grand Rounds Speaker – Vitiligo, Dept. of Dermatology, University of Texas, Southwestern
  11. Grand Rounds Speaker – Vitiligo, Dept. of Dermatology, New York University
  12. Grand Rounds speaker – Vitiligo, Dept. of Dermatology, University of California San Francisco
  13. Visiting Professor/Grand Rounds speaker – Vitiligo, Dept. of Dermatology, Northwestern University
  14. SDRC Grand Rounds speaker – Vitiligo, Dept. of Dermatology, Case Western Reserve University
  15. JDRF Center on Immunological Tolerance in Type-1 Diabetes at HMS – Vitiligo, Boston, MA
  16. Department of Dermatology – Vitiligo, Kyoto University, Kyoto, Japan
  17. Department of Dermatology – Vitiligo, Keio University, Tokyo, Japan

National/International Meetings invited speaker

  1. State of the Art Plenary Speaker - Vitiligo: from immunopathogenesis to targeted therapies, 2015 Society of Investigative Dermatology national meeting, Atlanta, GA
  2. Speaker – Vitiligo: from immunopathogenesis to targeted therapies, World Congress of Dermatology, Vancouver, Canada
  3. PASPCR Vitiligo workshop, invited speaker – Future Treatments in Vitiligo, Orange, CA
  4. ASPCR invited speaker – Translational Research in Vitiligo, Shanghai, China
  5. Speaker – Vitiligo, the Translational Research Revolution, 2015 AAD annual meeting
  6. Forum Director – Vitiligo, 2015 AAD annual meeting
  7. Chairman’s Lecturer – Vitiligo, Alopecia Areata, Wisconsin Dermatologic Society, Milwaukee, WI
  8. Plenary Speaker – Vitiligo Pathogenesis and Future Treatments, International Pigment Cell Conference (iPCC), Singapore
  9. Speaker – Vitiligo, Alopecia Areata, Indian Dermatologists Meeting, Cape Town, South Africa
  10. Speaker – Vitiligo, Alopecia Areata, Combined Mass./RI Academy Dermatology, Newport, RI
  11. Speaker – CXCL10 in vitiligo pathogenesis, Gordon Research Conference: chemokines, West Dover, VT
  12. Speaker – Update on Vitiligo – a Global Overview, 2014 AAD annual meeting
  13. Forum Director – Vitiligo, 2014 AAD annual meeting
  14. Dermatology Foundation Clinical Symposium – Vitiligo, Alopecia, Autoimmunity, Naples, Florida
  15. Speaker – Managing Vitiligo, Kuwait Derma Update and Laser Conference IV, Kuwait City, Kuwait
  16. Forum Director – Vitiligo, 2013 AAD annual meeting
  17. Speaker – Managing the Vitiligo Patient, 2013 AAD annual meeting
  18. VRF Round Table on Vitiligo, life sciences task force – vitiligo pathogenesis, Kitzbuhel, Austria
  19. NIH, NIAID invited workshop speaker, Humanized mice to study immunology of vector-borne diseases
  20. Focus Session –Autoimmunity, AAD 2012 Annual Meeting
  21. Focus Session – Vitiligo, AAD 2012 Annual Meeting
  22. Vitiligo Symposium, AAD 2012 Annual Meeting, San Diego, CA
  23. Cicatricial Alopecia Symposium, Washington DC
  24. Vitiligo Consensus Conference, Bordeaux, France (prior to iPCC)
  25. Alopecia Areata Research Focus Group, Washington DC
  26. Vitiligo pre-consensus conference, Seoul, Korea (Categories, clinical/research focus)
  27. Focus Session – Autoimmunity, AAD 2011 Annual Meeting
  28. Focus Session – Autoimmunity, American Academy of Dermatology (AAD) 2010 Annual Meeting

Vitiligo Publications:

Harris JE, Harris TH, Weninger W, Wherry EJ, Hunter CA, Turka LA. A mouse model of vitiligo with focused epidermal depigmentation requires IFN-γ for autoreactive CD8+ T cell accumulation in the skin. J. Invest. Dermatol. (2012) 132; 1869-1876. PMCID: 3343174

Harris JE. Viewpoint: Vitiligo and alopecia areata: Apples and oranges? Exp. Derm. (2013) 22(12): 785-9.

Richmond JM, Frisoli ML, and Harris JE. Innate immune mechanisms in vitiligo: Danger from within. Curr. Opin. Immunol. (2013) 25: 676-82.

Rashighi M, Agarwal P, Richmond JM, Harris TH, Dresser K, Su M, Zhou Y, Deng A, Hunter CA, Luster AD, and Harris JE. CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo. Science Transl. Med. (2014) 6(223): 1-10.

Eleftheriadou V, Thomas K, van Geel N, Hamzavi I, Lim H, Suzuki T, Katayama I, Anbar T, Abdallah M, Benzekri L, Gauthier Y, Harris J, Cesar C, de Castro S, Pandya A, Goh BK, Lan CE, Oiso N, Al Issa A, Esmat S, Le Poole IC, Lee AY, Parsad D, Taieb A, Picardo M, Ezzedine K and The Vitiligo Global Issues Consensus Group (VGICG). Developing core outcomes set for vitiligo clinical trials: International e-Delphi Consensus. PCMR. (2015) 28(3):363-9.

Agarwal P,Rashighi M, Essien KI, Richmond JM, Randall L, Pazoki-Toroudi HR, Hunter CA, Harris JE. Simvastatin prevents and reverses depigmentation in a mouse model of vitiligo. J. Invest. Dermatol. (2015) 135(4):1080-8.

Harris JE. IFN-γ in vitiligo, is it the fuel or the fire? Acta Derm Venereol. (2015) In press.

Other Publications:

Richmond JM and Harris JE. Immunology and Skin in Health and Disease, in The Skin and its Diseases. (2014) Cold Spring Harb Perspect Biol. doi:10.1101/CSHPERSPECT.a015339.

Richmond JM and Harris JE. Chapter 1109. The Pathobiologic Basis of Autoimmunity, in Vanguri, V.K. (Section Ed.), Section 1: Adaptive Immunity, in McManus, L.M. and Mitchell, R.N. (Eds.), Pathobiology of Human Disease: A Dynamic Encyclopedia of Disease Mechanisms. (in press) Elsevier.

Hemavathy K, Guru SC, Harris J, Chen JD, Ip YT. Human Slug is a repressor that localizes to sites of active transcription. Mol.Cell Biol. (2000) 20; 5087-5095.

Harris JE*, Bishop KD*, Phillips N, Mordes JP, Greiner DL, Rossini AA, Czech MP. Early growth response gene-2, a zinc-finger transcription factor, is required for full induction of clonal anergy in CD4+ T cells. J. Immunol. (2004) 173; 7331-7338. *Co first authors.

Harris JE, Sutton DA, Rubin A, Wickes B, de Hoog GS, Kovarik C. Exophiala spinifera as a cause of cutaneous phaeohyphomycosis: Case study and review of the literature. Med. Mycol. (2008) 47; 87-93.

Bishop KD, Harris JE, Mordes JP, Greiner DL, Rossini AA, Czech MP, Phillips N. Depletion of the Programmed Death-1 Receptor completely reverses established clonal anergy in CD4+ T lymphocytes via an Interleukin-2-dependent mechanism. Cell. Immunol. (2009) 256; 86-91.

Harris JE, Seykora JT, Lee RA. Renbök Phenomenon and Contact Sensitization in a Patient with Alopecia Universalis. Arch. Derm. (2010) 146; 422-425. PMCID: 2888038

Ramón HE, Cejas PJ, LaRosa D, Rahman A, Harris JE, Zhang J, Hunter C, Choi Y, Turka LA. EGR-2 Is not Required for In Vivo CD4 T Cell Mediated Immune Responses. PLoS ONE, (2010) 5; 1-7.

Harris JE, Marshak-Rothstein A. Interfering with B cell immunity. J. Leuk. Biol, (2011) 89; 805-806.

Chin MS, Freniere BB, Fakhouri S, Harris JE, Lalikos JF, Crosby AJ. Cavitation Rheology as a Potential Method for in vivo Assessment of Skin Biomechanics. Plast. Reconstr. Surg. (2013) 131(2): 303e-305e. PMCID: 3712129

MalhotraN, Narayan K, Cho OH, Sylvia K, Yin C, Melichar H, Rashighi M, Lefebvre V, Harris JE, Berg LJ and Kang J. A network of High Mobility Group box transcription factors programs innate IL-17 production. Immunity. (2013) 38(4):681-693. PMCID: 23562159.

Rashighi M, Agarwal P, Richmond JM, Harris TH, Dresser K, Su M, Zhou Y, Deng A, Hunter CA, Luster AD, and Harris JE. CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo. Science Transl. Med. (2014) 6(223): 1-10. PMCID: 4086941

Melnick L, Wanat KA, Novoa R, Harris J, Cotsarelis G, and Rosenbach M. Coexistent sarcoidosis and alopecia areata or vitiligo: a case series and review of the literature. J Clin Exp Dermatol Res. (2014) 5:236.

Eleftheriadou V, Thomas K, van Geel N, Hamzavi I, Lim H, Suzuki T, Katayama I, Anbar T, Abdallah M, Benzekri L, Gauthier Y, Harris J, Cesar C, de Castro S, Pandya A, Goh BK, Lan CE, Oiso N, Al Issa A, Esmat S, Le Poole IC, Lee AY, Parsad D, Taieb A, Picardo M, Ezzedine K and The Vitiligo Global Issues Consensus Group (VGICG). Developing core outcomes set for vitiligo clinical trials: International e-Delphi Consensus. Pigment Cell & Melanoma Research. (2015) 28(3):363-9.

Agarwal P, Rashighi M, Essien KI, Richmond JM, Randall L, Pazoki-Toroudi HR, Hunter CA, Harris JE. Simvastatin prevents and reverses depigmentation in a mouse model of vitiligo. Invest. Dermatol. (2015) 135(4):1080-8. PMCID: 4366328.

Wu S, Wen-Qing L, Cho E, Harris JE, Speizer F, Qureshi AA. Use of permanent hair dyes and risk of vitiligo in women. Pigment Cell & Melanoma Research. (2015) 28(6):744-6

Ezzedine K, Sheth V, Rodrigues M, Eleftheriadou V, Harris JE, Hamzavi I, Pandya AG. Vitiligo is not a cosmetic disease. Am. Acad. Derm. (2015) 73(5):883-5.

Zhang R, Borges CM, Fan MY, Harris JE, Turka LA. Requirement for CD28 in effector regulatory T cell Differentiation, CCR6 induction, and skin homing. Immunol. (2015) 195(9):4154-61. PMCID: 4610862.

Li JLY, Lim CH, Tay FW, Goh CC, Devi S, Malleret B, Lee B, Bakocevic N, Chong SZ, Evrard M, Tanizaki H, Lim HY, Russell B, Renia L, Zolezzi F, Poidinger M, Angeli V, St. John AL, Harris JE, Tey HL, Tan SM, Kabashima K, Weninger W, Larbi A, Ng LG. Neutrophils self-regulate immune complex-mediated cutaneous inflammation through CXCL2. Invest. Dermatol. (2016) 136(2):416-24.

Harris JE, Rashighi M, Nguyen N, Jabbari A, Clynes R, Christiano AM, Mackay-Wiggan J. Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata. Am. Acad. Derm. (2016) 74: 370-71. PMCID: 4718770.

Chong SZ, Evrard M, Devi S, Zhang Y, Tan L, Li JLY, Tan SM, Chan JKY, Balabanian K, Harris JE, Chen Q, Rénia L, Wang CI, Larbi A, Looney MR, Krummel MF, Randolph GJ, Ginhoux F, Hidalgo A, Bachelerie F, Ng LG. CXCR4 identifies transitional bone marrow premonocytes that replenish the mature monocyte pool for peripheral responses. Exp Med. (2016) 213(11): 2293-2314.

Vanderweil SG, Amano S, Ko W, Richmond JM, Kelley M, Makredes Senna M, Pearson A, Chowdary S, Hartigan C, Barton B, Harris JE. A double-blind, placebo-controlled, phase-II clinical trial to evaluate oral simvastatin as a treatment for vitiligo. Am. Acad. Derm. (2016) 76(1): 150-1.

Gan EY, Eleftheriadou V, Esmat S, Hamzavi I, Passeron T, Böhm M, Anbar T, Goh BK, Lan CE, Lui H, Ramam M, Raboobee N, Katayama I, Suzuki T, Parsad D, Seth V, Lim HW, van Geel N, Mulekar S, Harris J, Wittal R, Benzekri L, Gauthier Y, Kumarasinghe P, Thng ST, Silva de Castro CC, Abdallah M, Vrijman C, Bekkenk M, Seneschal J, Pandya AG, Ezzedine K, Picardo M, Taïeb A; VGICC. Repigmentation in vitiligo: position paper of the Vitiligo Global Issues Consensus Conference (VGICC). Pigment Cell & Melanoma Research. (2017) 30(1): 28-40.

Richmond JM, Essien KI, Bangari DS, Currimbhoy SD, Groom JR, Pandya AG, Youd ME, Luster AD, Harris JE. Keratinocyte-derived chemokines orchestrate T cell positioning in the epidermis during vitiligo and may serve as biomarkers of disease. Invest. Dermatol. (2017) 137: 350-8.

Richmond JM, Masterjohn E, Chu R, Tedstone J, Youd ME, Harris JE. CXCR3 Depleting Antibodies Prevent and Reverse Vitiligo in Mice. Invest. Dermatol. (2017) 137: 982-5.

Mohammad TF, Al-Jamal M, Hamzavi IH, Harris JE, Leone G, Cabrera R, Lim HW, Pandya AG, and Esmat SM. The Vitiligo Working Group recommendations for narrowband ultraviolet B treatment of vitiligo. Am. Acad. Derm. (2017) 76: 879-88.

Strassner J, Rashighi M, Refat MA, Richmond JM, and Harris JE. Suction blistering the lesional skin of vitiligo patients reveals useful biomarkers of disease activity. Am. Acad. Derm. (2017) 76: 847-55.

van Geel N, Boniface K, Seneschal J, Jacquemin C, Speeckaert R, Wolkerstorfer A, Bekkenk M, Lommerts JE, Hamzavi I, Pandya A, Eleftheriadou V, Ezzedine K, Giannarelli D, Gnarra M, Sperduti I, Prinsen C, Harris J, Taieb A, Picardo M. Meeting report: Vitiligo Global Issues Consensus Conference (VGICC) Workshop "Outcome measurement instruments" and Vitiligo International Symposium, Rome, Nov 30-Dec 3rd. Pigment Cell & Melanoma Research. (2017) 30: 436-443.

Liu LY, Strassner JP, Refat MA, Harris JE*, and King BA*. Repigmentation in vitiligo using the janus kinase inhibitor, tofacitinib, requires concomitant light exposure. Am. Acad. Derm. (2017) 77: 675-82. *Co-corresponding authors.

van Geel N, Wolkerstorfer A, Lommerts JE, Ezzedine K, Eleftheriadou V, Hamzavi I, Harris J, Picardo M, Taieb A, Prinsen CA, Bekkenk M, and Speeckaert R. Validation study of the Vitiligo Extent Score-plus (VESplus). Am. Acad. Derm. (2018) 78: 1013-15.

Korta DZ, Christiano AM, Bergfeld W, Duvic M, Ellison A, Fu J, Harris JE, Hordinsky MK, King B, Kranz D, Mackay-Wiggan J, McMichael A, Norris DA, Price V, Shapiro J, and Atanaskova-Mesinkovska N. Alopecia Areata is a medical disease. Am. Acad. Derm. (2018) 78: 832-834.

Van Geel N, Bekkenk M, Lommerts JE, Ezzedine K, Harris J, Hamzavi I, Eleftheriadou V, Picardo M, Taieb A, Prinsen C, Wolkerstorfer A, and Speeckaert R. The Vitiligo Extent Score (VES) and the VESplus are responsive instruments to assess global and regional treatment response in patients with vitiligo. Am. Acad. Derm. (2018) 79:369-71.

Mande P, Zirak B, Ko WC, Taravati K, Bride KL, Brodeur TY, Deng A, Dresser K, Jiang Z, Ettinger R, Fitzgerald KA, Rosenblum MD, Harris JE, and Marshak-Rothstein A. Fas ligand promotes an inducible TLR-dependent model of cutaneous lupus-like inflammation. Clin. Invest. (2018) 128:2966-78.

Richmond J, Strassner JP, Zapata L Jr., Garg M, Riding RL, Refat MA, Fan X, Azzolino V, Tovar-Garza A, Tsurushita N, Pandya AG, Tso JY, and Harris JE. Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo. Science Transl. Med. (2018) 10:1-9.

Richmond J, Strassner JP, Rashighi M, Agarwal P, Garg M, Essien KI, Pell LS, and Harris JE. Resident memory and recirculating memory T cells cooperate to maintain disease in a mouse model of vitiligo. Invest. Dermatol. (2019) 139:769-778.

Eleftheriadou V, Hamzavi I, Pandya AG, Grimes P, HarrisJE, Huggins RH, Lim HW, Elbuluk N, Bhatia B, Tovar-Garza A, Nahhas AF, Braunberger T, Ezzedine K. International initiative for outcomes (INFO) for vitiligo: workships with patients with vitiligo on repigmentation. Br J Dermatol. (2018) 180: 574-579.

Ezzedine K, Ahmed M, Tovar-Garza A, Hajj C, Whitton M, Pandya A, Altalhab S, Seneschal J, Harris J, Taieb C. Cross cultural validation of a short-form of the Vitiligo Impact scale (VIPs). Am. Acad. Derm. (2019) 81: 1107-1114.

Van Geel N, Wolkerstorfer A, Ezzedine K, Pandya AG, Bekkenk M, Grine L, Van Belle S, Lommerts JE, Hamzavi I, Harris JE, Eleftheriadou V, Esmat S, Kang HY, Kumarasinghe P, Lan CE, Parsad D, Raboobee N, Xiang FL, Suzuki T, Prinsen CA, Taieb A, Picardo M, Speeckaert R; participants of the Rome International VGICC/VIS Workshop. Validation of a physician global assessment tool for vitiligo extent: Results of an international vitiligo expert meeting. Pigment Cell & Melanoma Research. (2019) 32: 728-733.

Tkachenko E, Refat MA, Balzano T, Maloney ME, Harris JE. Patient satisfaction and physician productivity in shared medical appointments for vitiligo. Am. Acad. Derm. (2019) 81: 1150-1156.

van Geel N, Hamzavi I, Kohli I, Wolkerstorfer A, Lim HW, Bae JM, Lui H, Harris JE, Pandya AG, Guan STT, Abdallah M, Esmat S, Seneschal J, Speeckaert R, Grine L, Kang HY, Raboobee N, Xiang LF, Bekkenk M, Picardo M, Taieb A. Standardizing serial photography for assessing and monitoring vitiligo: a core set of international recommendations for essential clinical and technical specifications. Am. Acad. Derm. (2019) 83:1639-1646.

Damsky W, Patel D, Garelli CJ, Garg M, Wang A, Dresser K, Deng A, Harris JE, Richmond J, King B. JAK inhibition prevents bleomycin-induced fibrosis in mice and is effective in morphea patients. JID (2020) 140: 1446-49.

Lyons AB, Ghia D, Abdallah M, Abdel-Malek Z, Esmat S, Ezzedine K, Grimes P, Harris JE, Lui H, Manga P, Mi QS, Pandya A, Parsad D, Passeron T, Picardo M, Seneschal J, Silpa-Archa N, Taieb A, Xiang F, Lim HW, Hamzavi IH. Proceeding report of the second vitiligo international symposium (VIS) – November 9-10, 2018, Detroit, Michigan, USA. PCMR (2020) 33:637-41.

Azzolino V, Zapata L, Garg M, Gjoni M, Riding RL, Strassner JP, Richmond JM, Harris JE. JAK inhibitors reverse vitiligo in mice but do not deplete skin resident memory T cells. JID (2020) 141: 182-184.

Rosmarin D, Pandya AG, Lebwohl M, Grimes P, Hamzavi I, Gottlieb AB, Butler K, Kuo F, Sun K, Ji T, Howell MD, Harris JE. A Randomised Controlled Trial of Ruxolitinib Cream for Vitiligo Treatment. The Lancet (2020) 396: 110–20.

Abuabara K, Silverberg JI, Simpson EL, Paller AS, Eichenfield LF, Bissonnette R, Krueger J, Harris JE, Dalfonso L, Watkins SE, Crawford JM, Thaçi D, Guttman-Yassky E. International observational atopic dermatitis cohort to follow natural history and treatment course: TARGET-DERM AD study design and rationale. BMJ Open. 2020 Nov 27;10(11):e039928.

Riding RL, Richmond JM, Fukuda K, Harris JE. Type I interferon suppresses viral vector priming of CD8+ T cells during initiation of vitiligo and melanoma immunotherapy. PCMR (2020) Epub ahead of print.

Rodrugues M, Pandya AG, Hamzavi I, Ezzedine K, Bekkenk MW, and Harris JE. Treatment recommendations for patients with vitiligo during COVID-19. Austral J of Dermatol. (2021) Epub ahead of print.